BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The FDA just put BPC 157 on the calendar. July 2324 advisory panel votes on whether to restore legal compounding access for BPC 157, TB 500, and 5 more restricted peptides. This is the BPC 157: The Body Protection Compound Revolutionizing Regenerative Medicine 503Pharma